ACADIA PHARMACEUTICALS INC 4
4 · ACADIA PHARMACEUTICALS INC · Filed Sep 16, 2014
Insider Transaction Report
Form 4
Wells William McDowall
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2014-09-12−9,190→ 14,927 totalExercise: $1.36Exp: 2022-06-07→ Common Stock (9,190 underlying) - Exercise/Conversion
Common Stock
2014-09-12$1.36/sh+9,190$12,498→ 9,190 total - Sale
Common Stock
2014-09-12$29.15/sh−9,190$267,873→ 0 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2014.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.20 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- [F3]25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following June 8, 2012.